These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 39009505)

  • 21. Neurological and Psychiatric Adverse Events Associated with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer Patients: Insights from a Pharmacovigilance Study via the FDA Adverse Event Reporting System.
    Yu Z; Guan M; Liao X
    Clin Drug Investig; 2024 Oct; 44(10):789-798. PubMed ID: 39392584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Global burden of vaccine-associated rheumatic diseases and their related vaccines, 1967-2023: A comprehensive analysis of the international pharmacovigilance database.
    Oh J; Jo H; Park J; Lee H; Kim HJ; Lee H; Kang J; Hwang J; Woo S; Son Y; Kim S; Smith L; Rahmati M; Jacob L; Lee J; Lee JH; López Sánchez GF; Dragioti E; Udeh R; Veronese N; Soysal P; Woo HG; Yon DK
    Int J Rheum Dis; 2024 Aug; 27(8):e15294. PubMed ID: 39171515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A post-marketing pharmacovigilance study of avapritinib: Adverse event data mining and analysis based on the United States Food and Drug Administration Adverse Event Reporting System database.
    Rong L; Xie M; Jiang M; Qiu H; Kong L
    Br J Clin Pharmacol; 2024 Aug; 90(8):1816-1826. PubMed ID: 36702463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database.
    Zhou C; Peng S; Lin A; Jiang A; Peng Y; Gu T; Liu Z; Cheng Q; Zhang J; Luo P
    EClinicalMedicine; 2023 May; 59():101967. PubMed ID: 37131541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database.
    Sun R; Ning Z; Qin H; Zhang W; Teng Y; Jin C; Liu J; Wang A
    Sci Rep; 2024 Apr; 14(1):9552. PubMed ID: 38664423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thromboembolic events in Janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration's Adverse Event Reporting System.
    Dong Z; Ye X; Chen C; Wang R; Liu D; Xu X; Zhou X; He J
    Br J Clin Pharmacol; 2022 Sep; 88(9):4180-4190. PubMed ID: 35466415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
    Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
    Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.
    Chen W; Cai P; Zou W; Fu Z
    Front Endocrinol (Lausanne); 2024; 15():1330936. PubMed ID: 38390214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pregnancy-related adverse events associated with statins: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS).
    Wu T; Shi Y; Zhu B; Li D; Li Z; Zhao Z; Zhang Y
    Expert Opin Drug Saf; 2024 Mar; 23(3):313-321. PubMed ID: 37612600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS).
    Huang J; Zhao Y; Cao Y; Zhang Q; Ran D; Li J; Luo L; Qiu F; Meng L
    Int J Clin Pharm; 2022 Aug; 44(4):993-1003. PubMed ID: 35776375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infection associated with CDK4/6 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system database.
    Chen J; Tang L; Song W; Sun C; Zhang W
    Front Pharmacol; 2024; 15():1371346. PubMed ID: 39011505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM; Zangardi ML; Moy B; Bardia A
    Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer.
    Samuel Eziokwu A; Varella L; Lynn Kruse M; Jia X; Moore HCF; Thomas Budd G; Abraham J; Montero AJ
    Clin Breast Cancer; 2021 Jun; 21(3):205-209. PubMed ID: 33189562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-World Treatment Patterns and Clinical Outcomes among Patients Receiving CDK4/6 Inhibitors for Metastatic Breast Cancer in a Canadian Setting Using AI-Extracted Data.
    Moulson R; Feugère G; Moreira-Lucas TS; Dequen F; Weiss J; Smith J; Brezden-Masley C
    Curr Oncol; 2024 Apr; 31(4):2172-2184. PubMed ID: 38668064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse drug events associated with fluorouracil use in patients with metastatic colorectal cancer: a real-world pharmacovigilance study based on the FDA adverse event reporting system.
    Zhao R; Han M; Lin S; Lin Z; Yu M; Zhang B; Ma L; Li D; Peng L
    Expert Opin Drug Saf; 2024 Oct; 23(10):1295-1307. PubMed ID: 39010662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
    Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
    Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse Event Assessment of Upadacitinib: A Pharmacovigilance Study Based on the FAERS Database.
    Yuan J; Lu H; Zuo X; Yin L; Pu Y; Zhang J
    Pharmacoepidemiol Drug Saf; 2024 Oct; 33(10):e70030. PubMed ID: 39385705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety analysis of Oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting system.
    Li Y; Wang X; Liao Y; Zeng Y; Lin W; Zhuang W
    BMC Infect Dis; 2024 May; 24(1):446. PubMed ID: 38724914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Toxicity signals associated with secukinumab: A pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database.
    Zheng Y; Guo X; Chen C; Chi L; Guo Z; Liang J; Wei L; Chen X; Ye X; He J
    Br J Clin Pharmacol; 2023 Feb; 89(2):865-873. PubMed ID: 36106653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.